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Introduction
The conference "Application of Molecular Biomarkers in
Epidemiology," was held at the National Institute of En-
vironmental Health Sciences, February 21-22, 1990. The
primaryobjectiveoftheconference was toprovide anup-to-date
review ofsomeofthemolecularbiomarkers currentlyavailable
inordertopromotediscussionbetweenlaboratoryscientistsand
epidemiologists ontheutility ofthesebiomarkers. Biomarkers
are indicators of molecular and cellular events in biological
systemsthat mayallowepidemiologists andotherhealthprofes-
sionals tobetterexaminetherelationshipsbetweenenvironmen-
talhazardsandhumanhealtheffects. Biomarkersfallintothree
basiccategories: biomarkersofdose, effect, andsusceptibility.
Many laboratories areusingmolecularbiology andsophisticated
chemical techniques todevelop suchbiomarkers, but their ap-
plication inepidemiological studieshasbeenquitelimited sofar.
The current and future use ofbiomarkers in epidemiological
studies atSuperfund sitesand inthe workplace wasdiscussed.
Thisconference reportisformattedsomewhatdifferently from
theotherreportsoftheSuperfundBasicResearchPrograminits
series ofconferences in 1990. The biomarkers conference was
differentinitspresentationinthattheseriesofshorttalksbythe
participants wereused asdiscussionpoints tobeexpandedatthe
variousroundtables. Theconferenceconsistedofsixsessionsof
15-min presentations and two round-table discussions. On the
first day, there were two sessions on biomarkers of car-
cinogenesisandbiomarkers ofchemical exposure, which were
followedby around-tablediscussion ontheusefulness ofthese
biomarkermethods inepidemiology. A further sessionoftalks
oncorrelation studiesinanimalmodelsfollowed. Onthesecond
day, there werethreesessionsof15-mintalksfollowedby a2 hr
round-tablediscussionattheendoftheday. Thefirsttwosessions
'Department ofBiomedical and Environmental Health Sciences, School of
Public Health, University ofCalifornia, Berkeley, CA.
2Superfund Basic Research Program, Division ofExtramural Research and
Training, NationalInstituteofEnvironmental Health Sciences, ResearchTriangle
Park, NC 27709.
Address reprint requests toW. A. Suk, Superfund Basic Research Program,
DivisionofExtramural ResearchandTraining, National InstituteofEnvironmen-
tal Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709.
This paper waspresented attheInternational Biostatistics Conference inthe
Study ofToxicology that was held May 13-25, 1991, in Tokyo, Japan.
described biomarkers ofindividual phenotypic variability and
biomarkersofhealtheffects otherthancancer, andthelastses-
sionfocusedonthecurrentuseofbiomarkersinepidemiological
studies. A summary ofthe conference program is provided in
the Appendix.
Biomarkers of Carcinogenesis
The first session was chaired by M. T. Smith (University of
California,Berkeley)and . B.Weinstein(ColumbiaUniversity).
Smith began the session by recounting recent progress in our
understanding ofthecancerprocessandtheimpliedlessons for
biomarkers. WorkbyVogelsteinandothersclearlyindicatesthat
genetic alterations occur throughout the cancer process.
Moreover, these genetic changes arenotonly point mutations,
butchromosome-wideeventssuchasaneuploidy-induction and
translocations. Screening chemicals for their ability to induce
genetic damage should therefore involve looking at many dif-
ferentendpoints.
Molecular biology advances should allow investigators to
evaluatechemicals muchmorerapidlythancurrentcytogenetic
approaches. W. Thilly (MassachusettsInstituteofTechnology)
characterizedanapproachthatinvolvestheuseofahigh-fidelity
polymerase chain reaction and denaturing gradient gel elec-
trophoresis. This method allows his group to amplify specific
segments ofDNA (e.g. an exon or coding region ofthe gene
coding for hypoxanthine-guanine phosphoribosyl transferase;
hprt)andtostudythespectrumofmutationsproducedbychem-
ical exposure and by spontaneous/background events. Thilly
describedmutational spectraproducedbyvariouschemicalsin-
cludinghydrogenperoxideandspontaneousevents, andshowed
howtheydiffermarkedly. Hesuggestedthatthisrapidandsim-
plemethodologycouldbeusedonlargenumbersofpeople, in-
dividuallyandaspooledsamples, toidentifymutational spectra
characteristic of particular chemical exposures. Thilly's ap-
proach oflooking directly at the genotype differs from, but is
complementaryto, thattakenbyR. Albertini(UniversityofVer-
mont), whoaddressedthe selectionoflymphocyteswith amu-
tantphenotyperesultingfromchangesintheirhprtgene. These
lymphocytescanthenbeanalyzedforthenatureofthemutations
inhprt. Albertini recountedhowdeletions atleastaslargeas 5
megabasescanbetoleratedathprtlocus(ontheX-chromosome)
and how different clones oflymphocytes can be produced bySMITHAND SUK
differenttypesofmutationathprt. Albertini'sgrouphas shown
thatthemutantfrequencyathprtinnewbornsismuchlowerthan
inadultsandincreaseswithage. Moreover,hprtinlymphocytesis
sensitive to smoking. Thus, epidemiological studiesusinghprt
mutational analysis would have to control for both age and
smoking.
Anothergene that is used to analyze for genetic mutation in
humans is the genethatcodes fortheglycophorinAproteinon
thesurfaceofredbloodcells. W. Bigbee (LawrenceLivermore
National Laboratory) reported on thedevelopment ofstate-of-
the-art flow cytometric methods to measure mutations in the
glycophorin A gene. Because red blood cells do not contain
DNA, the redmutational eventsmustoccurinthebonemarrow
precursorcells. Thus, glycophorinAisparticularlysuitablefor
screeninghumanexposuretomutagenicchemicalsthatactonthe
bone marrow to potentially cause leukemia and other hemato-
logical disorders. This group recentlypublished anew version
oftheglycophorinAassaythatcanbeperformedoncommercial-
ly available flow cytometers.
Different methods of measuring micronuclei (small DNA-
containing membrane-bound vesicles outside the main cell
nucleus) thatariseviachromosomelagorfragmentationinper-
ipheral blood cells were reported on by J. T. MacGregor (SRI
International). Micronuclei are potentially important for the
detection ofaneuploidogens and clastogens.
G. Lucier (National Institute of Environmental Health
Sciences) reported how his group has compared different
biomarkers in vitro includingcorrelating DNAadductformation
with various genetic end points. One new assay of genetic
damagetheyhavehelpeddevelop measures nucleoid sedimen-
tation and correlates closely with DNA strand breakage.
At the end ofthe session, Weinstein discussed the need for
markersofepigenetic eventsincarcinogenesis aswellasonesof
genetic alterations. He reviewed the need for biomarkers of
clonal cell proliferation and discussed the role of increased
protein kinase C activity in promoting cancer. His group is
studying the relationship between increased "phorbin" gene
expressionandproteinkinaseCactivation. Theyplantomeasure
releaseofthephorbingeneproductintotheserumasapossible
markerofthis activation andclonal cellproliferation.
Biomarkers of Chemical Exposure
The second session began with B. Hammock (University of
California, Davis)reviewing andevaluatingimmunologicalap-
proaches toassesshumanexposuretotoxicchemicals. Herelated
how immunoassayscouldbeusedinpractical aswell asmecha-
nistic studies, in environmental monitoring to study food
residues, groundwater contamination, and spills at waste
disposal sites. Biologicalmonitoringcouldalsobefacilitated, as
immunoassays for a numberofprotein and DNAadducts have
been developed. Another potential use of antibodies is the
cleanupofsamplesby immunoaffinity chromatography before
more elaborate chemical analysis.
R. Haas(CaliforniaDepartmentofHealthServices)expanded
uponthisdialogue, reporting ontheproductionofantibodies to
detect altered blood proteins for biological monitoring. He
depicted attempts tosynthesizehemoglobin adducts ofstyrene
oxide and hydroquinone, and to generate antibodies to these
modifiedbloodproteins. Themajorobstacle tothisprocedure
hasbeen theneed to overcome the extreme immunogenicity of
hemoglobin, so that a minor modification by a particular en-
vironmental toxicant may not lead to production ofantibodies
against the adduct, only against hemoglobin. Both Hammock
andHaas stressedtheimportanceofhaptensynthesis. Covering
thefunctional groupofimportanceduringcouplingtoacarrier
isacommoncauseoffailuretoproducethedesiredantibodies.
The formation of polycyclic hydrocarbon esters in human
hemoglobin and their characterization by synchronous fluor-
escence spectrometry was reported on by P. Skipper (Massa-
chusetts Institute of Technology). Using this state-of-the-art
technique, hisgroupfoundinhumanbloodaveragelevelsof3-10
pole of benzo[a]pyrene/g globin, which was unaffected by
smoking status. A new method forlooking atcysteine residues
orcysteinyl adductsofbloodproteinswasrecountedby S. Rap-
paport(UniversityofNorthCarolina,ChapelHill). Raneynickel
is used to cleave the C-Sbond between the adducted chemical
and the cysteine residue and to subsequently measure the re-
leased product. His group has thus measured adducts formed
between styreneoxideandhemoglobinoralbuminintheblood
ofstyrene-exposed workers. Using data from both in vitro and
in vivoexperiments, Raneydeterminedtheamountofalkylation
by styrene oxide. He calculated that the method he described
coulddetectexposuresbetween0.4and4.0ppminworkersand
approximately 0.2-2.0 ppm in the general population, The
method, which shouldbeapplicable to many otherchemicals,
isbeing refined to improve sensitivity.
DNA-proteincrosslinks areamajorformofgeneticdamage
thatcanbe readily analyzed. M. Costa (New YorkUniversity)
illustrated thatincellsexposedtocisplatinumorchromium VI,
fourmajorproteins werecomplexedtotheDNA. Costa'sgroup
hasunambiguously identifiedtheproteincrosslinkedtotheDNA
as actin, based onproteolytic maps, reaction with an actin an-
tibody, andalterations inrestriction enzymedigestionofDNA
containingthecrosslinkedprotein. However, whencellsareex-
posedtoformaldehyde, histones, notactin, arecomplexedtothe
DNA. Thus, particular classes ofchemicals may produce dif-
ferentprotein-DNAcrosslinks. Inadditiontobeingapromising
biomarker ofexposure, DNA-protein crosslinking is a major
form ofgenetic damage and one that persists during cell pro-
liferation. Costasuggestedthisapproachcouldbeusedtoiden-
tify exposure to particular groups oftoxic chemicals and also
delineated a new technology for measuring DNA-protein
crosslinks that relies on SDS-PAGE gel electrophoresis and
electroblotting.
Recounting his experience in measuring DNA adducts in
human populations, K. Hemminki (University of Helsinki)
described using the 32P-postlabeling procedure and im-
munoassaystodeterminetheformationofDNAadducts inFin-
nish foundry workers. Rather than absolute quantitation of
polycyclic aromatichydrocarbon(PAH) DNAadductformation,
he used a score ofadduct formation to express his results. He
gavethefoundryworkersa2.1 adductscore. Aftervacation, they
had a 1.0 adduct score, demonstrating that adduct levels were
transientandstableforonlyapproximately 1 month. Hemminki
then compared PAH-DNA adducts in Polish foundry workers
andinlocalandruralresidents. Thescoreinlocalresidentswas
almost as high as in the foundry workers, both ofwhich were
significantlyhigherthanintherural area. Thisemphasizesthe
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importanceofassessingbackgroundenvironmental exposurein
any studies ofworkerpopulations. Hefurther stated thatquan-
titative aspects of32P-postlabeling were notsufficiently studied
anddescribed thedifficulties inproducing quantitative numbers
withthesemethods. 32P-postlabeling canbestbeusedtoassess
relative exposures ratherthanabsolutelevelsofexposure/dose.
Urinary metabolites can also be used to assess chemical ex-
posures. Whilethesemaybetransientinnature, itis important
to note that alarge majority ofchemicals are converted mainly
to urinary metabolites, which makes this relatively simple
screening approach widely applicable.
A. Buckpitt(UniversityofCalifornia, Davis)definedthepo-
tential for monitoring naphthalene exposure through urinary
metabolites. Becausethe IS,2Repoxideofnaphthaleneisthema-
jorbinding speciesandpulmonarytoxicant, Buckpittrelatedthe
importanceofscreening forthe IS, 2Rmercapturicacidinurine
when quantitating the biologically important doseofnaphtha-
lene. Bycomparing ittothe 1R,2Slevels, onecandeterminethe
ability ofpeopleto convert naphthalene to anactivemetabolite
capable ofcausing injury to the lung.
Round-Table Discussion 1
Thechargetothefirstround-tablediscussants wastoevaluate
whether the biomarkers described in the first two sessions
(biomarkers of carcinogenesis and biomarkers of chemical
exposure) meet the necessary epidemiological criteria. The
round-table discussion clearly indicated the tremendous com-
munication gap between many practicing epidemiologists and
those laboratory scientists currently developing molecular
biomarkers. The major points raised can be summarized as
follows. Epidemiologists needwell-characterized, simple, sen-
sitive, andinexpensive waysofassessing exposureandhealthef-
fects orpredictors ofhealth effects that can beapplied to large
populations. Laboratory scientists tend to wanttobeonthecut-
ting edge ofthe development ofnew biomarkers and are con-
tinuously pushing forward using the latest techniques (and
associated jargon) in developing such methods. Although
laboratory scientiststendtobeconsistentlydissatisfiedwiththeir
present product, epidemiologists are willing to use these
methodsbeforealltheproblemsassociatedwiththemethodsare
worked out.
Epidemiologists argue that the utility ofthe newtechnology
has tobetestedinthefield, wherepopulations areexposed toa
varietyofpotentially hazardous substances. Intheirstudyofthe
associations between exposure to toxic chemicals and various
diseaseendpoints, epidemiologists oftenfindexposureassess-
menttobeoneofthemainproblemsofepidemiological studies.
Epidemiologists areeagertotryoutnewtoolsthatmayprove
to be more sensitive andaccurate inorder to betterunderstand
therelationships betweentheprocesses leading fromexposure
todisease. Thisapplies especially toenvironmental exposures
thataffect many people, yetthe responses elicitedby exposure
arerelativelylowandhomogeneouslydistributedsothatnewand
more sensitive detection methods aresorely needed. Epidemi-
ologists also pointed out that laboratory scientists need to be
aware that the methods they develop can only be applied in
accessible tissues and that this tissue may have tobe frozen or
preserved in some manner before analysis. Issues relating to
stabilityofbiomarkersduringstoragewerethereforediscussed,
andlaboratory scientistswereencouragedtostudythisinmore
detail. R. Montesano (International Agency for Research on
Cancer) raised the point that the prevalence of genetically
susceptible subpopulations may significantly influencethe range
of background levels in the general population, and better
characterization ofthesesubgroups will beessential.
Correlation Studies in Animal Models
J. Swenberg (University ofNorth Carolina, Chapel Hill) il-
lustratedhowhisgrouphasmeasuredDNAadductformation in
tissuesofrodentsexposedtothecarcinogensvinylchlorideand
ethyleneoxide. Ethyleneoxideisabraincarcinogen inrodents
andforms themostDNAadducts inthis tissue, but italso pro-
ducesconsiderablelevelsofDNAadductsinnontargettissues.
Studies inanimalmodelscanthereforebeusedtocorrelateapar-
ticular biomarker with subsequentcarcinogenic outcome.
Comparing various biomarkers in rodent studies using
benzene, butadiene, and other compounds, R. Henderson
(Lovelace InhalationToxicology ResearchInstitute), reportedon
how82-91% ofthemetabolizeddoseofthesechemicalswascon-
verted to urinary metabolites detectable for only 48 hr. She
pointedout, however, thatgiventhislargepercentageconversion
rate, urinarymetabolitesshouldbeaneffectivebiomarkerofcon-
tinuouslow-levelexposures. Only0.1-0.4% ofthemetabolized
dosewasconvertedtohemoglobinadducts, butsuchadductsdo,
ofcourse, accumulate. Shefurtherwarnedofthedangersofus-
ingrathemoglobinasasurrogateforhumanhemoglobin, asthe
formerismoresensitivetoalkylation. Mousehemoglobinseems
to be a far moreappropriate animal model.
Attheendofthefirstday, G. Wogan(Massachusetts Institute
ofTechnology)reportedonworkinhislaboratorythatcorrelated
theformationofDNAadductsinratliverwiththeactivationof
rasoncogenesandthesubsequentdevelopmentoflivertumors.
Theanalyticalmethodsusedtodetecttheirpresenceatanearly
stagearereadilyapplicabletohumantissuesandmaytherefore
provideameansfordetectionofearlypremalignantchangesin
humans exposed to environmental carcinogens. Wogan has
shown that chemicals representative of the generic class of
genotoxic chemicals (i.e., chemicals that have the ability to
damageDNAandcausemutationsandcancer)havebeenshown
toactivateoncogenesbyinducing similarmutations, anddetec-
tionoftheseinpreneoplasticcellsmayprovideasensitivemeans
todetecthazardous environmental exposures.
Biomarkers of Individual
Phenotypic Variability
The seconddaybeganwithdescriptionsofseveral new ways
ofassessing differences in theability ofhumans to metabolize
various chemicals, either to toxic ornontoxic products. There
are substantial differences in the levels ofparticular enzymes
involved in the metabolism ofchemicals in people. These dif-
ferences seemtoberelatedtobothgeneticandenvironmental in-
fluences. Especially interesting were the depictions ofnonin-
vasivemethodsallowingepidemiologiststocharacterizeagiven
individual'sabilitytometabolizecertaingroupsofchemicals. An
exampleofthiswasthemethodrelatedbyM. A. Butler(National
Center for Toxicologic Research), which requires humans to
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drink coffee andthen have theirurineanalyzed for the manner
in which they metabolize caffeine. This has been found to be
associated with their levels of cytochrome P-450 IA2, which
demethylatescaffeine atthe3-positionto 1,7-dimethylxanthine.
By determining the ratio ofthis 1,7-metabolite to others in the
urine, it ispossible toassess an individual's P-450IA2 activity
level. This isimportantbecausethisP450enzymecatalyzesthe
first step of arylamine activation to metabolites that are car-
cinogenic inthebladder. Studies inItalianandChinesepopula-
tions have shown abimodal distribution ofactivity with <30%
ofthe populations having high P-450 IA2 activity. Studies are
underway todetermine ifworkerswhodevelopedbladdercancer
fromexposuretoarylaminesarerapidcaffeinemetabolizerswith
high P-450 1A2 activity.
F. P. Guengerich (VanderbiltUniversity) recountedhowmore
than 20 cDNA sequences were known for human cytochrome
P-450s, butthree seemtopredominateintheirimportance inthe
activation ofprocarcinogens. These were P-450IA2, discussed
above, which is also called P-450PA and activates phenacetin,
arylamines, and food pyrolysis products; P-450 IIIA4, also
called P-45ONF, which metabolizes nifedipine, aflatoxins,
polycyclic dihydrodiols, and6-aminochrysene; andP-450IIE1,
also called P-450j, which metabolizes ethanol, benzene,
alkylnitrosamines, andchlorinatedhydrocarbons. TheseP-450s
are inducible(e.g., IA2bycigarette smoke, PAHsetc., andII1A4
by barbiturates). Noninvasive markers ofactivity areavailable
for IA2 (caffeine) and IIIA4 (nifedipine), and Guengerich's
group is actively working on a marker forIIEL.
About 40% of the human population lack the i class of
glutathione transferases through genedeletion. Previous studies
have shown acorrelationbetween lackofglutathionetransferase
itand lung cancerrisk. J. Wiencke(UniversityofCalifornia, San
Francisco) discussedhowhisgroupdemonstrated thatlympho-
cytes ofpersons lacking A transferasearemuch more suscepti-
ble to genetic damage from epoxides. He indicated, therefore,
thatlackofutransferasemaybeanimportantsusceptibility factor
for genetic damage from environmental carcinogens.
Differences intheabilityofhumans tometabolizechemicals
via acetylation are well known. W. Weber (University of
Michigan) reported howtherehasrecently beenmuchprogress
inunderstanding thedifferenceswithinthehumanpopulationof
the enzymes involved in these particular metabolic processes.
There ispromisethatwewill soonbeabletouseseveral nonin-
vasive techniques to characterize the differences in human
populations and their ability to metabolize chemicals.
Biomarkers of Health Effects
Other Than Cancer
ThefifthsessionopenedwithD. Katz(UniversityofCalifor-
nia, Davis), summarizinghowcomputer-assistedspermanalysis
can be used to assess male reproductive capability. Using this
technique, hislaboratory demonstrated thatperchloroethylene
exposurecancausesubtlechangesinspermmotility, whichmay
leadtoreducedfertility. AnotherresearcherfromtheUniversity
of California, Davis, B. Lasley, is developing biomarkers of
femalereproductivecapabilitybasedonnonradiometric assays
forurinarymetabolitesofpituitary, ovarian, andplacentalhor-
mones. Suchassayscouldprovidearapidmeansofdetectingear-
lypregnancylossandovarianfunctioninwomenexposedtotoxic
hazards. Muchworkneedstobedone, however, todeterminethe
endocrine profiles of reproductive abnormalities in normal
womenwiththesemethodsbeforethemethodscanbeeffectively
used in epidemiological studies.
The need for additional, practical biomarkers to screen for
birthdefectswasdiscussedby M. Khoury (Centers forDisease
Control). Cytogenetic characterization of markers such as
trisomyofchromosome21 inDowns syndromeshouldbecome
much easier with the application of chromosome-specific
fluorescenthybridization probes. Theapplicationofmolecular
technologiessuchasthepolymerasechainreactionshouldalso
makedetectionandcharacterization simplerbecauseonlyafew
cells are needed. In a series of population-based neurotox-
icological studies, L. Costa(UniversityofWashington) related
how human lymphocytes express many ofthe neurochemical
receptors found on nerve cells. This is an important research
advance and presents a myriad ofopportunities, empowering
human lymphocytes' useasaccessible surrogates fordopamine
and other neurochemical receptors on nerve cells. Analysis of
receptorlevels/occupancyonlymphocytesmaythereforeprovide
peripheral markers ofneurotoxic effects.
Itwas reportedby C. Snyder(New YorkUniversity) howdif-
ferent immune function assays can be used as indicators of
chemically induced immune systemdamage. Healsodiscussed
someoftheirassociatedpitfalls. A. Brody (National Institute of
Environmental Health Sciences) portrayed recent progress
towarddeveloping biomarkers ofpulmonary injury, especially
markers ofexposure to particulate matter. The best marker of
exposuretoparticlesisthedetectionoftheinhaledmaterial atthe
sites where the earliest inflammatory lesions and subsequent
diseasedevelop. Inanimal studies ithasbeenpossibletodeter-
minetheamountofparticulatesthatdepositonthebifurcations
of alveolar ducts. Whether such markers could be useful for
human studies isdifficulttopredict. Byusingautoradiography
itisalsopossibletomeasurecellproliferation inthelungandto
predict which cell populations are the first to respond to par-
ticulates and noxious agents. For further information on
biomarkers ofpulmonary toxicity, readers are referred to the
National Research Council monograph (1).
Liver damage and subsequent cell proliferation could be
measuredbyreleaseofcertainliver-specific growth factors in-
to the bloodstream. G. Michaelopoulos (Duke University
Medical Center)delineatedhow, forexample, hepatopoietin A
isa 100,000molecularweightlivercellmitogenandgrowthfac-
torthatisreleasedintothebloodduringregenerativecellgrowth
after liver damage. An ELISA assay has been developed to
measure this factor in blood, which may be a highly sensitive
biomarkerofsubtledamageandhepatic cell proliferation.
Use of Biomarkers in Epidemiology
Studies
Thefinal sessionoftheconferenceconcentrated onthecurrent
useofbiomarkers inepidemiological studies. Casehistoriesof
the use ofbiomarkers such as protein adducts, DNA adducts,
sister chromatid exchange (SCE), and micronuclei were re-
counted. S. Tannenbaum (Massachusetts Institute of Tech-
nology) began the session by characterizing the use of
hemoglobin adducts to assess exposure to arylamines such as
4-aminobiphenyl (ABP). Workingtogetherwithepidemiologists
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fromtheNational CancerInstituteandtheUniversityofTurin,
Italy, his group has shownthat ABPadduct levelsare higher in
smokersofblacktobacco(asopposedtoblondetobacco), which
is associated with ahigherriskofbladdercancer. Moreover, in
all groups, including nonsmokers, they found about a 50%
higheradductlevel inpersonsofthe slowacetylatorphenotype.
The adduct level was therefore affected by the type oftobacco
smoked and the individual's acetylator phenotype. F. Perera
(Columbia University) presented a series of large ongoing
epidemiological studies, the objective ofwhich is to correlate
various biomarkers of exposure, effect, and susceptibility in
humans exposed to styrene, aminobiphenyl, ethyleneoxide, and
polycyclic aromatic hydrocarbons. Similarly, J. Yager(Electrical
Power Research Institute) reported on a study performed on
styrene-exposed workers in Washington State. Extensive
industrial hygiene measurements ofworkerdosimetry wereper-
formed on this population so that correlations could be made
between worker exposure and various biomarkers. The
biomarkers studiedincludedDNAadducts, hemoglobinadducts,
and SCEandmicronuclei formation inperipherallymphocytes.
Only SCE induction data were fully analyzed at thetimeofthe
meeting, andYagerdelineated statistical approaches todetermin-
ing the relative contributions of styrene exposure, cigarette
smoking, age, and other factors. An approximate 10% chem-
ically related increase in SCE levels can be measured by this
approach with statistical significance in 20-40 individuals.
Round-Table Discussion 2
Inthefinal 2hroftheconference, asecondround-tablediscus-
sion was held. A group ofeightepidemiologists and agroup of
laboratory scientists were assembled. Both groups were asked
torespondtotwoquestions: Howcancurrentbiomarkersbeused
most effectively? What new types of biomarkers need to be
developed?
M. Schenker (University ofCalifornia, Davis) startedthedis-
cussion by emphasizing the need forbiomnarkers ofexposure
because of the importance of ascertaining exposures in
epidemiological studies. L. Fine (National Institute ofOccupa-
tional Safety and Health) followed with comments about how
biomarkersofexposurecouldbeusedinintervention studies to
test the effectiveness ofparticular control strategies. He then
raised an ethical concernregarding themisuseofbiomarkers of
susceptibility, cautioning thatthesebiomarkers couldpotentially
and incorrectly serve as a screening mechanism to exclude
groups of workers from the workplace. Fine concluded his
remarksbypointingoutthatmanyoccupationalandenvironmen-
tal studies are now evaluating nonclassical exposures, such as
those from electrical fields, and that biomarkers need to be
developed that can evaluate these kinds ofexposures.
C. Shy(UniversityofNorthCarolina, ChapelHill)focusedthe
discussion on ways of evaluating the effectiveness of using
biomarkers in field investigations. Thefeasibility ofbiomarkers
as anepidemiological toolcouldonlybedetermined, forexam-
ple, when the following information is known: what types of
samples need to be collected; how much ofthe samples canbe
stored; andhowlongthesamples canbestored. Shyraisedques-
tions aboutstudyandresearchdesignthathefeltwouldalsohave
tobeclarified, includingdeterminationofthesizeofthesample
required inorderto havesufficientpower, whether serial sam-
plingwouldbenecessary, theassociatedcostsofcarryingoutthe
studies, andthelevel ofexpertiserequiredboth inthe field and
inthelaboratory. Finally, Shyemphasizedtheneedtocorrelate
biomarkers with the standard techniques currently used to
evaluate exposures and the need for "gold standards" to assess
their validity.
The importance ofcorrelating thepresenceorlevel ofapar-
ticularbiomarkerwithaclinicaloutcomewashighlightedbyH.
Checkoway (University ofWashington). Through suchcorrela-
tion, thesignificanceofdetectingachangeinabiomarkercould
beascertained. HisremarkswerefollowedbyJ. Andrews (Agen-
cy forToxic Substances and DiseaseRegistry), who counseled
investigatorstousebiomarkersinfieldstudiessothatthevalidity,
sensitivity, andusefulnessofthestudiescouldbedetermined. A.
Caporaso (National CancerInstitute) concurred thatthe useof
biomarkersasmeasuresofexposure, dose, orsusceptibilitymust
be validated in epidemiological studies and urged epidemi-
ologists to workclosely with laboratory scientists.
Addressingtheuseofabiomarkerasatoolinepidemiological
investigations, A. Wilcox(National InstituteofEnvironmental
HealthSciences)pointedoutthatepidemiologists need simple,
well-characterized, repeatable standard assays that can be ap-
pliedinstudiesofhundreds orthousandsofpeople. Underscor-
ing those remarks, S. Swan (California Department ofHealth
Services)thendrewtheaudience'sattentiontothepotential pro-
blem ofsample and selection bias that would arise ifspecially
self-selected groups within thepopulation were more likely to
participate in studies where samples of urine or semen, for
example, were collectedon aregularbasis. She also suggested
conducting paired studies to compare the more traditional
epidemiological measures with biomarkers currently being
developed.
Perera concluded the discussion among the first group of
scientistsby suggestingthatthemosteffectiveuseofbiomarkers
wouldbetoincorporatetheminaseriesorbatteryofteststobe
performed in a population-based study, and including both
specific andgeneric types ofmarkers. Shealsocommented on
theutilityofcomparingbiomarkers inhumanandanimal studies
andhow suchcorrelativestudieswouldprovideopportunitiesto
more fully validatepromisingbiomarkers.
ThesecondgroupofscientistsassembledwithSmithleading
thediscussion. Hepointedouttheimportanceofbiomarkersof
effectbecauseofthe latency periodoften involvedwith cancer
and other forms of disease. He also raised the prospect of
technologytransferoftechniquescurrentlybeingdevelopedand
suggested that the techniques could be transferred to large
governmentorcontractlaboratoriesthatcouldperformanalyses
onlargenumbersofsamples. Thiswouldhelpbridgethegapbe-
tweendevelopmentlaboratoriesandfieldepidemiologists. Final-
ly, Smithbroughtuptheethicaldilemmathatwillfacescientists
when studies are conducted involving individuals living near
Superfundsites. Whatdotheinvestigatorstellthepublic? How
doscientistsdisseminateinformationaboutthesignificanceof
thepresenceofbiomarkersandhowtheycorrelatetoriskofdis-
ease? How aretheuncertaintiesaboutriskestimatesexplained?
W. Suk(NationalInstituteofEnvironmental HealthSciences)
framedhiscommentswithinthecontextofthegoalsoftheSuper-
fundBasicResearchProgram. Hestressedtheimportanceofthe
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need for epidemiologists and molecular biologists to work
together in the development and validation ofadvanced tech-
niques forthedetection, assessment, andevaluationoftheeffects
onhumanhealthofhazardoussubstances, especiallyatlowlevels
of exposure. Furthermore, he explained that new and cogent
methodstoassesstheriskstohumanhealthpresentedbyhazard-
ous substances need tobeeffectively dealtwith ifone istotake
basic researchandimplementitpracticallyandproductively in
thefield. SukthenelaboratedonSmith'scommentsabouttech-
nology transfer and added that he viewed epidemiologists as
instrumental in carrying out this transfer as biomarkers are
moved from the laboratories to the field.
Emphasizing the necessity of developing predictive bio-
markers andurging thatthe scientificcommunity notsettlefor
poorly characterized markers, C. Harris (National Cancer In-
stitute) pointedoutthatsuchresearcheffortswillrequirealarge
expenditure offunds. Hecalled forcontinued investigation in-
to molecularmechanisms indevelopingbiomarkersofeffect for
cancer. Itishisopinionthatinvestigators shouldfocusfutureef-
forts ontumor-suppressor genes, notactivated oncogenes, and
concentrateondevelopingtechnologies formarkersofeffectin
thisarea. Hewasconfidentthatthesetoolswouldbeforthcom-
ing but that they would involve sophisticated techniques and
wouldbeexpensive. Harrisendedwithremarksaboutourgrow-
ingunderstanding ofgeneticpredisposition asafactoraffecting
an individual's risk ofdisease and reiterated earlier comments
about the ethical issues that are raised surrounding potential
worker discrimination issues.
Theneedtoincorporaterelevantbiomarkersintomonitoring
andanimalstudiesandtohavethesestudiesexaminedifferentend
pointstodetermineifthebiomarkersarepredictiveinthesemod-
elswasthefocusofYager'scomments. Shealsoraisedtheques-
tionofhowtodeterminewhenanassayisrobustenough(i.e., pre-
dictableenough, sensitiveenough, specificenough) tobeused.
Finally, sheunderscoredtheneedtoidentifythesourcesofbiolog-
icalvariabilityinthedevelopmentandapplicationofbiomarkers.
Thefinalremarks fromthegroupcamefromWogan, whore-
emphasized comments madeearlieraboutthepracticability and
accessibility ofthe samplematerial. Headdedthatapplication
of biomarkers to broad segments ofthe population would be
limitedunlesstechniquesdevelopedinthelaboratoriescouldbe
translated into field procedures applied to readily accessible
bodily fluids. Wogan thenprovidedthegroup withahistorical
perspectivebypointing outthatthedevelopmentofsciencehas
beendriven inthepastbytheemergenceofnew andimportant
technologies and that he foresaw an exciting period ofcancer
research ahead. Furthermore, as technologies acquired
usefulness, theassociatedcostswoulddeclineandhewashopeful
thatthe newbiomarkertechnologiescurrently beingdeveloped
could be made costeffective.
Summary
Theprincipalconclusionsandopportunitiesthatcanbedrawn
fromthisconference areasfollows. Themeetingdemonstrated
the large communication gap that still exists between most
epidemiologists andlaboratory scientists. Thisproblemcouldbe
overcome if epidemiologists worked closely with laboratory
scientists attheoutsetofanyproject sothatabetterunderstand-
ingcouldbebuiltbetweenthem. Epidemiologistsneedsimple,
well-characterized, reproducible assays that can be applied to
hundreds orthousands ofpeople. Mostlaboratory scientists have
littleinterestinrunninglargenumbersofassays, butwishtocon-
tinually refine their methods so that they stay on the "cutting
edge" ofbasicresearch. Thisproblemcouldbeovercomeifthe
new laboratory technology could be transferred to contract
laboratories or small companies. Problems of technology
transfer therefore need to be addressed. Current and new
biomarkersneedtobebettervalidatedinthefieldandby study-
inganimalmodels. Moreinformationonthebackgroundexpres-
sionofbiomarkers inthegeneralpopulationisneeded(i.e. what
isthenormalrange?). Ethical issues, suchasthepossibilitythat
biomarkers of susceptibility could be used to exclude people
from the workplace, need tobe addressed.
Appendix
ApplicationofMolecularBiomarkers in
Epidemiology: Program
Welcome and NIEHS view
D. Rall, NIEHS
Introduction to Meeting
M. Smith, University ofCalifornia, Berkeley
Epidemiological criteria fortheperfectbiomarker
R. Neutra, NIEHS
IARC viewofbiomarkers
R. Montesano,
Session I
Overview, biomarkers ofgeneticdamage
M. Smith, University ofCalifornia, Berkely
Mutational spectraathprtandother loci
W. Tilly, Massachusetts InstituteofTechnology
hprt Mutations inT-lymphocytes
R. Albertini, University ofVermont
Glycophorin Aassay
W. Bigbee, Lawrence Livermore National Laboratory
Micronuclei formation in humanblood cells
J. McGregor, SRI International
Relationships between various markers ofdamage inblood cells
G. Lucier, NIEHS
Biomarkers ofpromotion
B. Weinstein, Columbia University
Session 11
Overview, immunological approaches toassessing exposure
B. Hammock, UniversityofCalifornia, Davis
Monoclonal antibodies tobloodprotein adducts
R. Haas, California Department ofHealth Services
PAH esters inhumanhemoglobin
P. Skipper, Massachusetts InstituteofTechnology
Cysteinyl adducts inbloodproteins
S. Rappaport, University ofNorth Carolina, Chapel Hill
DNA-protein crosslinks as biomarkersofexposure
M. Costa, New YorkUniversity
DNA adducts asbiomarkers
K. Hemminki, University ofHelsinki
Urinary metabolites
A. Buckpitt, University ofCalifornia, Davis
Session III
Relationships between DNAadducts, cell proliferation, andcarcinogenesis
J. Swenberg, University ofNorthCarolina, Chapel Hill
Correlationsofhemoglobinadducts, DNAadducts, andurinary metabolites
R. Henderson, LovelaceInhalation Toxicology ResearchInstitute
Correlations between DNA modifications, oncogeneactivation, and
hepatocarcinogenesis
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Session IV
G. Wogan, Massachusetts Institute ofTechnology
Phenotypic differences in cytochrome P-450
F. P. Guengerich, Vanderbilt University
Arylamine carcinogenesis and caffeine 3-demethylation as a biomarker
in humans
M. A. Butler, National Center for Toxicological Research
Human glutathione transferase itdeficiency
J. Wiencke, University ofCalifornia, San Francisco
Acetyltransferase polymorphism
W. Weber, University ofMichigan
Session V
Assessment ofmale reproductive capability
D. Katz, University ofCalifornia, Davis
Assessment offemale reproductive capability
B. Lasley, University ofCalifornia, Davis
Biomarkers ofbirth defects
M. Khoury, Centers for Disease Control
Peripheral markers ofneurotoxicity
L. Costa, University ofWashington
Immune function assays as indicators oftoxicant exposure
C. Snyder, New York University
Biomarkers oflung injury
A. Brody, National Institute ofEnvironmental Health Sciences
Biomarkers ofliver injury
G. Michalopoulos, Duke University Medical Center
Session VI
Arylamines
S. Tannenbaum, Massachusetts Institute ofTechnology
Polycyclic aromatic hydrocarbons and othercarcinogens
F.Perera, Columbia University
Styrene
J. Yager, Electrical PowerResearch Institute
Peripheral markers ofstyrene toxicity
H. Checkoway, University ofWashington
Aflatoxin
J. Groopman, Johns Hopkins University
Inherited predisposition and moleculardosimetry incancer risk
C. Harris, National Cancer Institute
ThesuccessofthisConferenceisdueinlargeparttotheinvaluablecontributions
oftheSteeringCommittee members: MartynSmith, Chair(UniversityofCalifor-
nia, Berkeley), James Fouts (National Institute of Environmental Health
Sciences), Fred Guengerich (VanderbiltUniversity), Bruce Hammock (Univer-
sity ofCalifornia, Davis), William Suk (National Institute ofEnvironmental
Health Sciences), and Steve Tannenbaum (Massachusetts Institute of
Technology). TheauthorsalsoacknowledgethevaluableassistanceofPenelope
J. E. Compton, Elaine Symanski, and Claudia Hopenhayn-Rich, all of the
University ofCalifornia, Berkeley, insummarizingthepresentationsthatform
thebasisofthismeetingreport; andtoSueHaithcock, NationalInstituteofEn-
vironmental Health Sciences, forassistance intypingandformattingthereport.
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